- Home
- NCDL vs GERN Comparison
NCDL vs GERN Comparison
Compare NCDL & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCDL
- GERN
- Stock Information
- Founded
- NCDL 2019
- GERN 1990
- Country
- NCDL United States
- GERN United States
- Employees
- NCDL N/A
- GERN N/A
- Industry
- NCDL
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- NCDL
- GERN Health Care
- Exchange
- NCDL NYSE
- GERN Nasdaq
- Market Cap
- NCDL 819.6M
- GERN 853.5M
- IPO Year
- NCDL N/A
- GERN 1996
- Fundamental
- Price
- NCDL $16.42
- GERN $1.40
- Analyst Decision
- NCDL Hold
- GERN Buy
- Analyst Count
- NCDL 4
- GERN 7
- Target Price
- NCDL $16.31
- GERN $4.17
- AVG Volume (30 Days)
- NCDL 255.2K
- GERN 9.8M
- Earning Date
- NCDL 08-06-2025
- GERN 08-07-2025
- Dividend Yield
- NCDL 12.97%
- GERN N/A
- EPS Growth
- NCDL N/A
- GERN N/A
- EPS
- NCDL N/A
- GERN N/A
- Revenue
- NCDL N/A
- GERN $116,293,000.00
- Revenue This Year
- NCDL N/A
- GERN $160.12
- Revenue Next Year
- NCDL N/A
- GERN $55.01
- P/E Ratio
- NCDL N/A
- GERN N/A
- Revenue Growth
- NCDL N/A
- GERN 22264.04
- 52 Week Low
- NCDL $14.21
- GERN $1.17
- 52 Week High
- NCDL $18.01
- GERN $5.06
- Technical
- Relative Strength Index (RSI)
- NCDL 54.68
- GERN 44.45
- Support Level
- NCDL $15.99
- GERN $1.36
- Resistance Level
- NCDL $16.72
- GERN $1.57
- Average True Range (ATR)
- NCDL 0.29
- GERN 0.10
- MACD
- NCDL -0.02
- GERN -0.02
- Stochastic Oscillator
- NCDL 50.00
- GERN 25.00
About NCDL NUVEEN CHURCHILL DIRECT LENDNG CORP
Nuveen Churchill Direct Lending Corp is a specialty finance company focused predominantly on investing in senior secured loans to private equity-owned U.S. middle market companies. It invest in senior secured loans that typically pay floating interest rates and are senior in the capital structure to junior debt and equity.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.